Kashyap Patel: Identify patients likely to respond to Immunotherapy based on Episwitch CIRT

Kashyap Patel shared a post by EpiSwitch CiRT on LinkedIn, adding:

“We are embarking on a journey to identify patients likely to respond to Immunotherapy based on new and unique test Episwitch CIRT in a prospective real world evidence study (www.ccorn.net) to enable us to have a quick answer to start patients on highly effective I/O therapy.”

Quoting EpiSwitch CiRT’s post:

“Colleagues and collaborators are thrilled about the advancement of the PROWES study, which is further elucidating the clinical application and utility of CiRT for use in multiple oncological indications. The IRB-approved study is enrolling up to 2,500 patients across many nationally recognized oncology institutions.

Dr. Kashyap Patel, CEO and oncologist of Carolina Blood and Cancer Care Associates (primary trial site) highlights the impact of our very accurate (85%) CiRT test that predicts a patient’s response to immune checkpoint inhibitors, giving physicians a powerful tool for patient care management. Learn more and tune into updates at WorldCDx.”

Source: Kashyap Patel/LinkedIn and EpiSwitch CiRT/LinkedIn

Kashyap Patel is the Immediate Past President and a Board Member of the Community Oncology Alliance. He serves as a Medical Director (consultant) for Blue Cross Blue Shield of South Carolina and the International Oncology Network. He is also the President of Carolina Blood and Cancer Care.